AMENDMENTS TO THE CLAIMS

1.   **(Currently Amended)** A process of preparing cells for cell therapy, comprising the

steps of:

inducing helper T ~~Th~~ cells that have a nonspecific antitumor activity; and

imparting antigen specificity to the helper T ~~Th~~ cells

wherein the step of imparting antigen specificity to the helper T cells is carried out by

transducing a T cell receptor gene that recognizes a cancer-associated antigen.

2.   **(Cancelled)**

3.   **(Currently Amended)** The process for preparing cells for cell therapy according to

claim 1, wherein the step of imparting antigen specificity to the helper T ~~Th~~ cells is carried out

by transducing ~~a gene for~~ a class I-restricted T cell receptor gene ~~TCR~~ that recognizes a cancer-

associated antigen.

4.   **(Currently Amended)** The process for preparing cells for cell therapy according to

claim 1, wherein the step of imparting antigen specificity to the helper T ~~Th~~ cells is carried out

by transducing ~~a gene for~~ a class II-restricted T cell receptor gene ~~TCR~~ that recognizes a cancer-

associated antigen.

5.   **(Currently Amended)** The process for preparing cells for cell therapy according to any

of claims 1, 3 or 4 ~~2 to 4~~, wherein the cancer-associated antigen is selected from the group

GMM/EAC/kmlMM/EAC

consisting of <u>Wilms' Tumor 1</u> ~~WT1~~, CEA, AFP, CA19-9, CA125, PSA, CA72-4, SCC, MK-1, MUC-1, p53, HER2, G250, gp-100, MAGE, BAGE, SART, MART, MYCN, BCR-ABL, TRP, LAGE, GAGE, and NY-ESO1.

6.   **(Currently Amended)** The process for preparing cells for cell therapy according to claim 1, wherein the step of inducing <u>helper T</u> ~~Th~~ cells having a nonspecific antitumor activity is carried out by culturing a T cell-containing material in the presence of anti-CD3 antibody and IL-2.

7.   **(Currently Amended)** The process for preparing cells for cell therapy according to any of claims <u>1, 3, 4 or 6</u> ~~1 to 6~~, further comprising a step of purifying the <u>helper T</u> ~~Th~~ cells to which antigen specificity has been imparted.

8.   **(Currently Amended)** The process for preparing cells for cell therapy according to claim 7, wherein the step of purifying the <u>helper T</u> ~~Th~~ cells to which antigen specificity has been imparted is carried out by using antibody-bearing magnetic beads.

9.   **(Currently Amended)** A process of preparing cells for cell therapy, comprising the steps of:

    inducing <u>helper T 1</u> ~~Th1~~ cells and <u>cytotoxic T 1</u> ~~Tc1~~ cells that have a nonspecific antitumor activity; and

GMM/EAC/kmlMM/EAC

imparting antigen specificity to the <u>helper T 1</u> ~~Th1~~ cells and <u>cytotoxic T 1</u> ~~Tc1~~ cells <u>wherein the step of imparting antigen specificity to the helper T 1 cells and cytotoxic T 1 cells is carried out by transducing a T cell receptor gene that recognizes a cancer-associated antigen</u>.

10.   **(Cancelled)**

11.   **(Currently Amended)** The process for preparing cells for cell therapy according to claim 9, wherein the step of imparting antigen specificity to the <u>helper T 1</u> ~~Th1~~ cells and <u>cytotoxic T 1</u> ~~Tc1~~ cells is carried out by transducing ~~a gene for~~ a class I-restricted <u>T cell receptor gene</u> ~~TCR~~ that recognizes a cancer-associated antigen.

12.   **(Currently Amended)** The process for preparing cells for cell therapy according to claim 9, wherein the step of imparting antigen specificity to the <u>helper T 1</u> ~~Th1~~ cells and <u>cytotoxic T 1</u> ~~Tc1~~ cells is carried out by transducing ~~a gene for~~ a class II-restricted <u>T cell receptor gene</u> ~~TCR~~ that recognizes a cancer-associated antigen.

13.   **(Currently Amended)** The process for preparing cells for cell therapy according to <u>any</u> of claims ~~9 to 12~~ <u>9, 11 or 12</u>, wherein the cancer-associated antigen is selected from the group consisting of <u>Wilms' Tumor 1</u> ~~WT1~~, CEA, AFP, CA19-9, CA125, PSA, CA72-4, SCC, MK-1, MUC-1, p53, HER2, G250, gp-100, MAGE, BAGE, SART, MART, MYCN, BCR-ABL, TRP, LAGE, GAGE, and NY-ESO1.

GMM/EAC/kmlMM/EAC

14.   **(Currently Amended)** The process for preparing cells for cell therapy according to claim 9, wherein the step of inducing helper T 1 ~~Th1~~ cells and cytotoxic T 1 ~~Tc1~~ cells having a nonspecific antitumor activity is carried out by culturing a T cell-containing material in the presence of anti-CD3 antibody, IL-2, and IL-12.

15.   **(Currently Amended)** The process for preparing cells for cell therapy according to any of claims 9, 11, 12 or 14 ~~9 to 14~~, further comprising a step of separating the helper T 1 ~~Th1~~ cells and cytotoxic T 1 ~~Tc1~~ cells to which antigen specificity has been imparted.

16.   **(Currently Amended)** The process for preparing cells for cell therapy according to claim 15, wherein the process of separating the helper T 1 ~~Th1~~ cells and cytotoxic T 1 ~~Tc1~~ cells to which antigen specificity has been imparted is carried out by using antibody-bearing magnetic beads.

17.   **(Currently Amended)** The process for preparing cells for cell therapy according to claim 15 ~~or 16~~, further comprising a step of mixing the separated helper T 1 ~~Th1~~ cells and cytotoxic T 1 ~~Tc1~~ cells in any given proportion.

18.   **(Currently Amended)** Cells for cell therapy, that are produced by a process comprising the steps of:

          inducing helper T ~~Th~~ cells that have a nonspecific antitumor activity; and

GMM/EAC/kml MM/EAC

imparting antigen specificity to the <u>helper T</u> ~~Th~~ cells<u>, wherein the step of imparting antigen specificity to the helper T cells is carried out by transducing a T cell receptor gene that recognizes a cancer-associated antigen</u>.

19.   **(Currently Amended)** Cells for cell therapy, that are produced by a process comprising the steps of:

inducing <u>helper T 1</u> ~~Th1~~ cells and <u>cytotoxic T 1</u> ~~Tc1~~ cells that have a nonspecific antitumor activity; and

imparting antigen specificity to the <u>helper T 1</u> ~~Th1~~ cells and <u>cytotoxic T 1</u> ~~Tc1~~ cells<u>, wherein the step of imparting antigen specificity to the helper T 1 cells and cytotoxic T 1 cells is carried out by transducing a T cell receptor gene that recognizes a cancer-associated antigen</u>.

20.   **(Currently Amended)** A method for preventing or treating tumor, comprising the steps of:

isolating leukocytes from a patient;

inducing from the leukocytes <u>helper T</u> ~~Th~~ cells that have a nonspecific antitumor activity;

imparting antigen specificity to the <u>helper T</u> ~~Th~~ cells<u>, wherein the step of imparting antigen specificity to the helper T cells is carried out by transducing a T cell receptor gene that recognizes a cancer-associated antigen</u>; and

administering to the patient the <u>helper T</u> ~~Th~~ cells to which antigen specificity has been imparted.

GMM/EAC/kmlMM/EAC

21.   **(Currently Amended)** A method for preventing or treating tumor, comprising the steps of:

isolating leukocytes from a patient;

inducing from the leukocytes helper T 1 ~~Th1~~ cells and cytotoxic T 1 ~~Tc1~~ cells that have a nonspecific antitumor activity;

imparting antigen specificity to the helper T 1 ~~Th1~~ cells and cytotoxic T 1 ~~Tc1~~ cells, wherein the step of imparting antigen specificity to the helper T 1 cells and cytotoxic T 1 cells is carried out by transducing a T cell receptor gene that recognizes a cancer-associated antigen; and

administering to the patient the helper T 1 ~~Th1~~ cells and cytotoxic T 1 ~~Tc1~~ cells to which antigen specificity has been imparted.

GMM/EAC/kmlMM/EAC